Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: A randomised, double-blind, placebo-controlled, parallel-group trial

British Journal of Nutrition

Volumn 114, Issue 10, 2015, Pages 1638-1646

  Eskesen, Dorte ^a   Jespersen, Lillian ^a   Michelsen, Birgit ^a   Whorwell, Peter J ^b   Müller Lissner, Stefan ^c   Morberg, Cathrine M ^a  

^a CHR HANSEN A S   (Denmark)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c Park Klinik Weissensee   (Germany)

Author keywords

Bifidobacterium animalis subsp. lactis; Bowel habits; Defecation frequency; Gastrointestinal well being; Probiotics

Indexed keywords

BB 12; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM ANIMALIS; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DEFECATION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; FEMALE; FRANCE; GASTROINTESTINAL DISEASE; GERMANY; HUMAN; MALE; MULTICENTER STUDY; NONHUMAN; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM; ABDOMINAL PAIN; BIFIDOBACTERIUM; MIDDLE AGED; ODDS RATIO; PATIENT COMPLIANCE; QUESTIONNAIRE; TIME FACTOR;

ABDOMINAL PAIN; ADULT; BIFIDOBACTERIUM; DEFECATION; DOUBLE-BLIND METHOD; FEMALE; FRANCE; GERMANY; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT COMPLIANCE; PLACEBOS; PROBIOTICS; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; UNITED KINGDOM;

EID: 84945464520     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114515003347     Document Type: Article

References (49)

1. Simren M, Barbara G, Flint HJ, et al. (2013) Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 62, 159-176.
2. Ringel Y & Carroll I (2009) Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am 19, 141-150.
3. Lee KN & Lee OY (2014) Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 20, 8886-8897.
4. Bischoff SC (2011) 'Gut health': a new objective in medicine? BMC Med 9, 24.
5. Konig J & Brummer RJ (2014) Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome. Benef Microbes 5, 247-261.
6. Ford AC, Bercik P, Morgan DG, et al. (2014) Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. Aliment Pharmacol Ther 39, 312-321.
7. Drossman DA, Corazziari E, et al. (2006) Rome III: The Functional Gastrointestinal Disorders, 3rd ed. McLean, VA: Degnon Associates.
8. Krogsgaard LR, Engsbro AL & Bytzer P (2013) The epidemiology of irritable bowel syndrome in Denmark. A population-based survey in adults 50 years of age. Scand J Gastroenterol 48, 523-529.
9. Canavan C, West J & Card T (2014) The epidemiology of irritable bowel syndrome. Clin Epidemiol 6, 71-80.
10. Canavan C, West J & Card T (2014) Review article: The economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 40, 1023-1034.
11. Choung RS, Branda ME, Chitkara D, et al. (2011) Longitudinal direct medical costs associated with constipation in women. Aliment Pharmacol Ther 33, 251-260.
12. Choung RS, Shah ND, Chitkara D, et al. (2011) Direct medical costs of constipation from childhood to early adulthood: a population-based birth cohort study. J Pediatr Gastroenterol Nutr 52, 47-54.
13. Whitehead WE & Drossman DA (2010) Validation of symptombased diagnostic criteria for irritable bowel syndrome: a critical review. Am J Gastroenterol 105, 814-820.
14. European Food Safety Authority Panel on Dietetic Products, Nutrition and Allergies (2011) Guidance on the scientific requirements for health claims related to gut and immune function. EFSA J 9, 1984.
15. Trentacosti AM, He R, Burke LB, et al. (2010) Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am J Gastroenterol 105, 731-735.
16. Spiegel BM, Hays RD, Bolus R, et al. (2014) Development of the NIH patient-reported outcomes measurement information system (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol 109, 1804-1814.
17. Irvine EJ, Whitehead WE, Chey WD, et al. (2006) Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 130, 1538-1551.
18. European Agency for the Evaluation of Medicinal Products (2003) Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. London: European Agency for the Evaluation of Medicinal Products. http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003187.pdf
19. Nishida S, Gotou M, Akutsu S, et al. (2004) Effect of yogurt containing Bifidobacterium lactis BB-12 on Improvement of defecation and fecal microflora of healthy female adults. Milk Science 53, 71-80.
20. Pitkala KH, Strandberg TE, Finne Soveri UH, et al. (2007) Fermented cereal with specific bifidobacteria normalizes bowel movements in elderly nursing home residents. A randomized, controlled trial. J Nutr Health Aging 11, 305-311.
21. Uchida K, Akashi K, Kusunoki I, et al. (2005) Effect of fermented milk containing Bifidobacterium lactis Bb-12 on stool frequency, defecation, fecal microbiota and safety of excessive ingestion in healthy female students-2nd report. J Nutr Food 8, 39-51.
22. Muller-Lissner S, Koch G, Talley NJ, et al. (2003) Subject's global assessment of relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 56, 310-316.
23. Pimentel M, Lembo A, Chey WD, et al. (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364, 22-32.
24. Hungin AP, Mulligan C, Pot B, et al. (2013) Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice-an evidence-based international guide. Aliment Pharmacol Ther 38, 864-886.
25. Guyonnet D, Schlumberger A, Mhamdi L, et al. (2009) Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutr 102, 1654-1662.
26. Marteau P, Guyonnet D, Lafaye de Micheaux P, et al. (2013) A randomized, double-blind, controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifidobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms. Neurogastroenterol Motil 25, 331-e252.
27. Craig CL, Marshall AL, Sjostrom M, et al. (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35, 1381-1395.
28. Simren M, Ohman L, Olsson J, et al. (2010) Clinical trial: The effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - A randomized, double-blind, controlled study. Aliment Pharmacol Ther 31, 218-227.
29. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6, 65-70.
30. Corazziari E, Bytzer P, Delvaux M, et al. (2003) Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther 18, 569-580.
31. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2012) Guidance for industry. Irritable bowel syndrome-clinical evaluation of drugs for treatment. http://www. fda.gov/downloads/Drugs/Guidances/UCM205269.pdf (accessed February 2015).
32. European Medicines Agency, Committee for Medicinal Products for Human Use (2014) Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome.
33. Fedorak RN, Vanner SJ, Paterson WG, et al. (2012) Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol 26, 252-256.
34. Gupta SK (2011) Intention-to-treat concept: a review. Perspect Clin Res 2, 109-112.
35. Muller-Lissner S (2013) Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments. Expert Opin Drug Metab Toxicol 9, 391-401.
36. Meance S, Cayuela C, Raimondi A, et al. (2003) Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis Strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Microb Ecol Health Dis 15, 15-22.
37. Larsen CN, Nielsen S, Kaestel P, et al. (2006) Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults. Eur J Clin Nutr 60, 1284-1293.
38. Whorwell PJ, Altringer L, Morel J, et al. (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101, 1581-1590.
39. Ringel-Kulka T, Palsson OS, Maier D, et al. (2011) Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders - A double-blind study. J Clin Gastroenterol 45, 518-525.
40. Waller PA, Gopal PK, Leyer GJ, et al. (2011) Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol 46, 1057-1064.
41. Ouwehand AC, Donglian C, Weijian X, et al. (2014) Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine 32, 458-463.
42. Gao XW, Mubasher M, Fang CY, et al. (2010) Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficileassociated diarrhea prophylaxis in adult patients. Am J Gastroenterol 105, 1636-1641.
43. Saha L (2014) Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol 20, 6759-6773.
44. Wall GC, Bryant GA, Bottenberg MM, et al. (2014) Irritable bowel syndrome: a concise review of current treatment concepts. World J Gastroenterol 20, 8796-8806.
45. Jadallah KA, Kullab SM & Sanders DS (2014) Constipationpredominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol 20, 8898-8909.
46. Camilleri M (2009) Editorial: is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome? Am J Gastroenterol 104, 920-922.
47. Chang L & Drossman DA (2010) Rome Foundation Endpoints and Outcomes Conference 2009: optimizing clinical trials in FGID. Am J Gastroenterol 105, 722-730.
48. Bellini M, Gambaccini D, Stasi C, et al. (2014) Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol 20, 8807-8820.
49. Soares RL (2014) Irritable bowel syndrome: a clinical review. World J Gastroenterol 20, 12144-12160.